about
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesProspects for exosomes in immunotherapy of cancerCancer immunotherapy via dendritic cellsDirect stimulation of T cells by membrane vesicles from antigen-presenting cells.Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvantCancer vaccines and carbohydrate epitopes.Dendritic cells as therapeutic vaccines against cancer.Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4Evaluation of cancer-preventive activity and structure-activity relationships of 3-demethylubiquinone Q2, isolated from the ascidian Aplidium glabrum, and its synthetic analogs.Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy.Immunoepigenetics: the unseen side of cancer immunoediting.Tumor-associated antigens and biomarkers in cancer and immune therapy.Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus.Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.Human dendritic cell line models for DC differentiation and clinical DC vaccination studies.Dendritic cells: a critical player in cancer therapy?Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity.Dendritic cell-based therapy in Type 1 diabetes mellitus.Immunological perspective of self versus tumor antigens: insights from the RIP-gp model.Thymosin α1 and cancer: action on immune effector and tumor target cells.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Cancer vaccine adjuvants--recent clinical progress and future perspectives.A melanoma multiepitope polypeptide induces specific CD8+ T-cell response.Toll-like receptors targeting technology for the treatment of lymphoma.Cyclophosphamide potentiates the antitumor effect of immunization with injection of immature dendritic cells into irradiated tumor.An age-structured model of dendritic cell trafficking in the lung.Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cellsAutologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma.Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cellsTargeting the dendritic cell: the key to immunotherapy in cancer?Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients
P2860
Q26852437-2618AAC5-C803-47BE-8291-06E94DB416E8Q28248098-4E1E4CA8-4316-42B3-AA46-F3460849D1FCQ29615444-E1011567-9CB2-4923-A6B9-8360AD5D7D96Q34984478-2C836136-981D-4E5C-9E82-E1D2B9688BAAQ35319290-14CF55B2-BBCF-43F7-AB6A-0CF1A0EF52E9Q35525289-0FFD61F9-189A-4E50-BDEA-3396011C23CDQ36085614-7DA05468-0EB3-45E7-BD8E-332C72826D6BQ36399108-14377335-0B39-4FFF-B619-B27E73F60624Q36413897-2E85AA61-145A-40B8-9059-382C5161452CQ36430219-3ABACEB3-91D2-4CAF-8237-D7A27C8A8D9EQ36556729-FE46F882-B637-452D-9F88-D9495079B166Q36568984-3F7F4658-7BBC-4423-862F-930E9C897797Q36666346-5BB99135-063F-453B-AE25-805905804EBCQ36844959-916B1364-7ED0-4B6E-B1D6-BAE9800D5C80Q36897372-2CB4D920-3222-4854-B2D4-3D95CFB0E1BAQ37181792-DEADBECE-7F96-4CB2-B71E-3FCA962F403DQ37229552-AF08C2ED-9331-4EAB-A17A-FE126C1D9174Q37276138-4F742171-BCBC-46EC-8401-EB0E51D23C50Q37384753-45A52698-2D3C-4376-BEED-60C92E74ED22Q37754644-B6107E5B-F61E-4662-ADD3-0924628F72F6Q37864698-8B8F9BF1-B03A-4F15-9484-F07F40F7FBE3Q38050453-B9F6189E-0E5D-4F60-970A-2B1C8C5EA2E2Q38194135-693D2840-9316-4F47-8F69-D221576D7B9FQ38260496-F95DBC33-B724-46A7-A939-62D8177D5F8AQ38845278-8EE48709-D9FC-43A5-AAB4-6AC65A6C542BQ38948266-9235BE21-D859-42B9-A0F6-D442E22DC1D3Q39594003-E83733BA-6B72-48C6-93F3-5958359236B2Q40280731-9C92508A-650B-412B-ADCA-A9DD912EB18AQ41869921-2B40571E-E94F-4D57-AAF1-671D89D23827Q44437073-C0A0AD25-81F4-4C14-AB09-5F802FE1FDADQ50769076-4E527EBF-FAB5-4166-83D7-C5CDAC6841A1Q51059137-CDAE433B-D221-4B2E-91F0-D22F0D27D212Q53640046-98E0D87E-B9EF-4860-BB0D-73D0E004323CQ57133698-550A364B-D033-4E84-9867-5CFA424DFDE7Q57384884-72EBE6C7-1E5D-4546-8D47-2402E877C000Q58620001-8FB4BC14-A74A-42F3-B0C4-8D6170223868
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rational approaches to human cancer immunotherapy.
@en
type
label
Rational approaches to human cancer immunotherapy.
@en
prefLabel
Rational approaches to human cancer immunotherapy.
@en
P2093
P356
P1476
Rational approaches to human cancer immunotherapy.
@en
P2093
Ian D Davis
Jonathan Cebon
Phillip Parente
P356
10.1189/JLB.0502261
P50
P577
2003-01-01T00:00:00Z